Navigation Links
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Date:5/6/2009

Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting

SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies from its lead program, torezolid (TR-701), will be presented in an oral session and six poster presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Helsinki, Finland May 16-19. Torezolid is a novel antibiotic that recently completed Phase 2 clinical development with potent activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

The presentations are as follows:

Saturday, May 16th

Oral Presentation - Lecture Hall 3a (14:54 - 15:06)

  • O28: In vivo pharmacodynamics of TR-701, a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains; A. Louie, C. Fregeau, W. Liu, H. Conde, R. Kulawy, G. Drusano

Sunday, May 17th

Poster Presentations - New antimicrobials against Gram-positives (13:30 - 14:30)

  • P 1091: Effects of food on the pharmacokinetics of TR-701, a novel oxazolidinone prodrug antibiotic, in healthy adult subjects; KA. Munoz, P. Bien, P. Prokocimer, M. Berry, C. R. Bethune
  • P 1092: TR-700, a novel methyltetrazolyl-oxazolidinone, accumulates extensively within human macrophages cells and shows activity towards intraphagocytic linezolid-sensitive and linezolid-resistant S. aureus; S. Lemaire, K. Kosowska-Shick, P. Appelbaum, F. Van Bambeke, P. Tulkens
  • P 1090: The safety of single ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
  • P 1089: The safety of multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
  • P 1103: Characterization of resistance following serial passage of Staphylococcus aureus in the presence of the novel oxazolidinone TR-700 and linezolid; J. Locke, K. Shaw
  • P 1104: Characterization of the novel oxazolidinone TR-700 and linezolid spontaneous mutation frequencies and resistance mechanisms in Staphylococcus aureus; J. Locke, K. Shaw

Copies of these posters will be available on the Trius Web site following the ECCMID meeting: http://www.triusrx.com/posters.php.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has recently completed Phase 2 testing of torezolid in a U.S. based multi-center trial. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
2. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
3. Trius Doses First Patient in Antibacterial Phase 2 Trial
4. PacificGMP Completes GMP Product Fill for Trius Therapeutics
5. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
6. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
7. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
8. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
9. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
10. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
11. Vantia Therapeutics Pipeline Continues to Mature
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Fla. , Feb. 11, 2016 PLAD, ... started out 2016 with sales exceeding company targets, are ... have received their trademark from the United States Patent ... Bobby Clark , Chief Executive Officer of PLAD, Inc.  ... of Pennsylvania with two new ...
(Date:2/11/2016)... Feb. 11, 2016  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the engagement of Lars E. ... Medical Consultant. Dr. Birgerson will provide strategic medical ... operations team to help ensure timely facilitation of ...
(Date:2/11/2016)... ENGLEWOOD, Colo. , Feb. 11, 2016  Aytu ... on developing treatments for urological and related conditions, announced ... for the second fiscal quarter of 2016 on Tuesday, ... will review recent accomplishments and provide an overview of ... financial results for the quarter ended December 31, 2015. ...
Breaking Medicine Technology:
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most Promising ... team dedication and commitment to the SharePoint ecosystem. A panel of experts and ... goal is to recognize and promote technology entrepreneurship. , The survey was made ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and sports ... sensor for resistance cord exercise and therapy, introduces its new microFET Digital Pinch ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... coverage results in significantly higher rates of several common cancer screenings, especially among ... in better outcomes and survival rates. , The study,“What Does Medicaid Expansion ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified clinical ... of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve their ... series, known as “Mindfulness for Actors and Artists,” has been featured in ...
Breaking Medicine News(10 mins):